Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
DBV Technologies S.A. Stock Forecast NASDAQ:DBVT
Price Target and Analyst Ratings
Historical Ratings
| Date | Upside / Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 2021-12-21 | 249.65% | JMP Securities | $8.00 $5.00 | Maintains | Market Outperform |
| 2021-12-21 | 599.3% | HC Wainwright & Co. | $14.00 $10.00 | Maintains | Buy |
| 2020-08-05 | 39.86% | Morgan Stanley | $4.00 $2.00 | Maintains | Equal-Weight |
| 2020-08-05 | 879.02% | HC Wainwright & Co. | $25.00 $14.00 | Maintains | Buy |
| 2020-04-06 | 599.3% | Citigroup | $14.00 $10.00 | Maintains | Buy |
| 2020-03-18 | 179.72% | Morgan Stanley | $11.00 $4.00 | Maintains | Equal-Weight |
| 2020-03-17 | 319.58% | Stifel | $18.00 $6.00 | Downgrades | Buy Hold |
| 2020-01-09 | 1158.74% | Stifel | $10.00 $18.00 | Upgrades | Hold Buy |
| 2019-12-16 | 879.02% | Citigroup | $14.00 | Initiates Coverage On | Buy |
| 2019-06-17 | 879.02% | Goldman Sachs | $14.00 | Initiates Coverage On | Buy |
DBVT Stock Trend
The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.
Given the current short-term trend, the stock is expected to fall -7.95% during the next 3 months and, with a 90% probability hold a price between $1.01 and $1.50 at the end of this 3-month period.
WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2022-05-23 | $1.10 | $1.36 | $1.62 |
| 2022-05-24 | $1.10 | $1.36 | $1.62 |
| 2022-05-25 | $1.09 | $1.36 | $1.62 |
| 2022-05-26 | $1.09 | $1.35 | $1.62 |
| 2022-05-27 | $1.09 | $1.35 | $1.61 |
| 2022-05-31 | $1.09 | $1.35 | $1.61 |
| 2022-06-01 | $1.08 | $1.35 | $1.61 |
| 2022-06-02 | $1.08 | $1.34 | $1.61 |
| 2022-06-03 | $1.08 | $1.34 | $1.61 |
| 2022-06-06 | $1.08 | $1.34 | $1.60 |
| 2022-06-07 | $1.08 | $1.34 | $1.60 |
| 2022-06-08 | $1.07 | $1.34 | $1.60 |
| 2022-06-09 | $1.07 | $1.33 | $1.60 |
| 2022-06-10 | $1.07 | $1.33 | $1.59 |
| 2022-06-13 | $1.07 | $1.33 | $1.59 |
| 2022-06-14 | $1.06 | $1.33 | $1.59 |
| 2022-06-15 | $1.06 | $1.32 | $1.59 |
| 2022-06-16 | $1.06 | $1.32 | $1.58 |
| 2022-06-17 | $1.06 | $1.32 | $1.58 |
| 2022-06-21 | $1.05 | $1.32 | $1.58 |
| 2022-06-22 | $1.05 | $1.31 | $1.58 |
| 2022-06-23 | $1.05 | $1.31 | $1.58 |
| 2022-06-24 | $1.05 | $1.31 | $1.57 |
| 2022-06-27 | $1.05 | $1.31 | $1.57 |
| 2022-06-28 | $1.04 | $1.31 | $1.57 |
| 2022-06-29 | $1.04 | $1.30 | $1.57 |
| 2022-06-30 | $1.04 | $1.30 | $1.56 |
| 2022-07-01 | $1.04 | $1.30 | $1.56 |
| 2022-07-05 | $1.03 | $1.30 | $1.56 |
| 2022-07-06 | $1.03 | $1.29 | $1.56 |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product which is in Phase III clinical trials for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trials for the treatment of CMPA and milk-ind... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
